CRISPR Therapeutics
A Switzerland-headquartered biotech translating its CRISPR/Cas9 gene-editing platform into therapies to treat hemoglobinopathies, cancer, diabetes and other diseases.
The company's lead program, targeting the blood diseases β-thalassemia and sickle cell disease, has entered clinical testing, and its work in immuno-oncology, focused on CRISPR/Cas9-edited allogeneic CAR-T cell therapies, could be transformative.
CRISPR has a collaboration with Vertex Pharmaceuticals in Duchenne muscular dystrophy and myotonic dystrophy Type 1 which, if successful, could earn the company more than $1 billion.
Latest CRISPR Therapeutics News & Features
13 February 2024
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze